25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALA (Arovella) Stock Analysis
Buy, Hold or Sell?

Let's analyze Arovella together

I guess you are interested in Arovella Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Arovella’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Arovella’s Price Targets

I'm going to help you getting a better view of Arovella Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arovella Therapeutics Ltd

I send you an email if I find something interesting about Arovella Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Arovella (30 sec.)










1.2. What can you expect buying and holding a share of Arovella? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$0.03
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$0.03
Return On Investment
28.6%

For what price can you sell your share?

Current Price per Share
A$0.09
Expected price per share
A$0.072 - A$0.12
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arovella (5 min.)




Live pricePrice per Share (EOD)
A$0.09
Intrinsic Value Per Share
A$-0.07 - A$-0.04
Total Value Per Share
A$-0.06 - A$-0.03

2.2. Growth of Arovella (5 min.)




Is Arovella growing?

Current yearPrevious yearGrowGrow %
How rich?$7.3m$2.4m$4.9m66.3%

How much money is Arovella making?

Current yearPrevious yearGrowGrow %
Making money-$5.7m-$6.7m$944.7k16.4%
Net Profit Margin-51,447.3%-2,508.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Arovella (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#617 / 872

Most Revenue
#612 / 872

Most Profit
#439 / 872

Most Efficient
#861 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arovella?

Welcome investor! Arovella's management wants to use your money to grow the business. In return you get a share of Arovella.

First you should know what it really means to hold a share of Arovella. And how you can make/lose money.

Speculation

The Price per Share of Arovella is A$0.088. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arovella.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arovella, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arovella.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-5.5%0.00-5.5%-0.01-6.4%-0.01-5.8%0.00-5.4%0.00-4.0%
Usd Book Value Change Per Share0.004.7%0.004.7%0.00-2.4%0.000.5%0.00-0.3%0.00-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.004.7%0.004.7%0.00-2.4%0.000.5%0.00-0.3%0.00-0.3%
Usd Price Per Share0.09-0.09-0.03-0.05-0.04-0.03-
Price to Earnings Ratio-18.97--18.97--5.82--9.32--9.15--8.61-
Price-to-Total Gains Ratio22.28-22.28--15.45--4.38--0.73-8.92-
Price to Book Ratio14.78-14.78-15.68-11.35-10.43-5.75-
Price-to-Total Gains Ratio22.28-22.28--15.45--4.38--0.73-8.92-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0579216
Number of shares17264
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (17264 shares)71.40-5.27
Gains per Year (17264 shares)285.60-21.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102862760-21-31
205715620-42-52
308578480-63-73
40114211340-84-94
50142814200-105-115
60171417060-127-136
70199919920-148-157
80228522780-169-178
90257025640-190-199
100285628500-211-220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.022.01.00.0%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%12.011.00.052.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%5.00.018.021.7%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%12.011.00.052.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arovella Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0060.0060%-0.003+152%0.001+895%0.000+107%0.000+106%
Book Value Per Share--0.0090.0090%0.003+197%0.006+49%0.006+57%0.010-1%
Current Ratio--6.4466.4460%3.103+108%4.639+39%3.851+67%3.154+104%
Debt To Asset Ratio--0.1550.1550%0.309-50%0.212-27%0.236-34%0.209-26%
Debt To Equity Ratio--0.1830.1830%0.447-59%0.280-35%0.330-45%0.283-35%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--176605375.480176605375.4800%62751471.600+181%90365092.272+95%77186845.165+129%47361925.625+273%
Eps---0.007-0.0070%-0.009+16%-0.008+5%-0.007-3%-0.005-28%
Ev To Ebitda Ratio---19.993-19.9930%-6.050-70%-10.025-50%-11.404-43%-8.777-56%
Ev To Sales Ratio--10388.55110388.5510%154.599+6620%3550.148+193%2202.360+372%1103.419+841%
Free Cash Flow Per Share---0.006-0.0060%-0.005-9%-0.006-4%-0.005-22%-0.004-36%
Free Cash Flow To Equity Per Share--0.0060.0060%-0.001+113%0.002+283%0.001+354%0.001+901%
Gross Profit Margin--1.1461.1460%1.043+10%1.063+8%1.038+10%1.019+12%
Intrinsic Value_10Y_max---0.042----------
Intrinsic Value_10Y_min---0.073----------
Intrinsic Value_1Y_max---0.004----------
Intrinsic Value_1Y_min---0.006----------
Intrinsic Value_3Y_max---0.012----------
Intrinsic Value_3Y_min---0.020----------
Intrinsic Value_5Y_max---0.020----------
Intrinsic Value_5Y_min---0.034----------
Market Cap104309922.816-59%165947604.480165947604.4800%59267001.600+180%84159142.272+97%72779877.965+128%45374816.425+266%
Net Profit Margin---514.473-514.4730%-25.084-95%-189.566-63%-121.396-76%-62.735-88%
Operating Margin---522.126-522.1260%-27.616-95%-192.742-63%-121.526-77%-63.162-88%
Operating Ratio--636.957636.9570%24.850+2463%229.496+178%143.527+344%74.037+760%
Pb Ratio9.290-59%14.78014.7800%15.679-6%11.346+30%10.433+42%5.751+157%
Pe Ratio-11.927+37%-18.974-18.9740%-5.821-69%-9.319-51%-9.152-52%-8.611-55%
Price Per Share0.088-59%0.1400.1400%0.050+180%0.071+97%0.061+128%0.038+266%
Price To Free Cash Flow Ratio-14.810+37%-23.561-23.5610%-9.260-61%-12.270-48%-13.372-43%-9.492-60%
Price To Total Gains Ratio14.005-59%22.28122.2810%-15.447+169%-4.381+120%-0.731+103%8.923+150%
Quick Ratio--6.2306.2300%3.084+102%4.454+40%3.646+71%2.823+121%
Return On Assets---0.658-0.6580%-1.861+183%-1.152+75%-1.082+64%-0.654-1%
Return On Equity---0.779-0.7790%-2.693+246%-1.535+97%-1.514+94%-0.901+16%
Total Gains Per Share--0.0060.0060%-0.003+152%0.001+895%0.000+107%0.000+106%
Usd Book Value--7390300.5357390300.5350%2488055.896+197%4963951.328+49%4705106.236+57%7499766.501-1%
Usd Book Value Change Per Share--0.0040.0040%-0.002+152%0.000+895%0.000+107%0.000+106%
Usd Book Value Per Share--0.0060.0060%0.002+197%0.004+49%0.004+57%0.006-1%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--116241658.141116241658.1410%41303018.607+181%59478303.733+95%50804381.487+129%31173619.446+273%
Usd Eps---0.005-0.0050%-0.006+16%-0.005+5%-0.005-3%-0.003-28%
Usd Free Cash Flow---4635842.797-4635842.7970%-4212720.901-9%-4448954.147-4%-3634455.474-22%-2963360.809-36%
Usd Free Cash Flow Per Share---0.004-0.0040%-0.004-9%-0.004-4%-0.003-22%-0.003-36%
Usd Free Cash Flow To Equity Per Share--0.0040.0040%-0.001+113%0.001+283%0.001+354%0.000+901%
Usd Market Cap68656791.197-59%109226713.269109226713.2690%39009540.453+180%55393547.443+97%47903715.676+128%29865704.171+266%
Usd Price Per Share0.058-59%0.0920.0920%0.033+180%0.047+97%0.040+128%0.025+266%
Usd Profit---5756640.237-5756640.2370%-6701365.228+16%-6044025.496+5%-5599879.771-3%-4122309.364-28%
Usd Revenue--11189.40011189.4000%267162.064-96%157684.535-93%198611.192-94%1433934.379-99%
Usd Total Gains Per Share--0.0040.0040%-0.002+152%0.000+895%0.000+107%0.000+106%
 EOD+2 -6MRQTTM+0 -0YOY+29 -93Y+28 -105Y+25 -1310Y+21 -17

3.3 Fundamental Score

Let's check the fundamental score of Arovella Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.927
Price to Book Ratio (EOD)Between0-19.290
Net Profit Margin (MRQ)Greater than0-514.473
Operating Margin (MRQ)Greater than0-522.126
Quick Ratio (MRQ)Greater than16.230
Current Ratio (MRQ)Greater than16.446
Debt to Asset Ratio (MRQ)Less than10.155
Debt to Equity Ratio (MRQ)Less than10.183
Return on Equity (MRQ)Greater than0.15-0.779
Return on Assets (MRQ)Greater than0.05-0.658
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Arovella Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.752
Ma 20Greater thanMa 500.094
Ma 50Greater thanMa 1000.085
Ma 100Greater thanMa 2000.095
OpenGreater thanClose0.088
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Arovella Therapeutics Ltd

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Fundamental data was last updated by Penke on 2025-06-27 13:10:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Arovella earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Arovella to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -51,447.3%Β means thatΒ $-514.47 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arovella Therapeutics Ltd:

  • The MRQ is -51,447.3%. The company is making a huge loss. -2
  • The TTM is -51,447.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-51,447.3%TTM-51,447.3%0.0%
TTM-51,447.3%YOY-2,508.4%-48,938.9%
TTM-51,447.3%5Y-12,139.6%-39,307.7%
5Y-12,139.6%10Y-6,273.5%-5,866.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51,447.3%-91.7%-51,355.6%
TTM-51,447.3%-140.3%-51,307.0%
YOY-2,508.4%-196.4%-2,312.0%
3Y-18,956.6%-247.9%-18,708.7%
5Y-12,139.6%-343.3%-11,796.3%
10Y-6,273.5%-488.1%-5,785.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Arovella is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Arovella to theΒ Biotechnology industry mean.
  • -65.8% Return on Assets means thatΒ Arovella generatedΒ $-0.66 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arovella Therapeutics Ltd:

  • The MRQ is -65.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -65.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-65.8%TTM-65.8%0.0%
TTM-65.8%YOY-186.1%+120.3%
TTM-65.8%5Y-108.2%+42.4%
5Y-108.2%10Y-65.4%-42.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-65.8%-11.5%-54.3%
TTM-65.8%-11.5%-54.3%
YOY-186.1%-11.4%-174.7%
3Y-115.2%-11.7%-103.5%
5Y-108.2%-11.9%-96.3%
10Y-65.4%-13.7%-51.7%
4.3.1.3. Return on Equity

Shows how efficient Arovella is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Arovella to theΒ Biotechnology industry mean.
  • -77.9% Return on Equity means Arovella generated $-0.78Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arovella Therapeutics Ltd:

  • The MRQ is -77.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -77.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-77.9%TTM-77.9%0.0%
TTM-77.9%YOY-269.3%+191.4%
TTM-77.9%5Y-151.4%+73.5%
5Y-151.4%10Y-90.1%-61.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-77.9%-13.6%-64.3%
TTM-77.9%-14.8%-63.1%
YOY-269.3%-14.4%-254.9%
3Y-153.5%-16.8%-136.7%
5Y-151.4%-17.5%-133.9%
10Y-90.1%-19.5%-70.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arovella Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Arovella is operatingΒ .

  • Measures how much profit Arovella makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Arovella to theΒ Biotechnology industry mean.
  • An Operating Margin of -52,212.6%Β means the company generated $-522.13 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arovella Therapeutics Ltd:

  • The MRQ is -52,212.6%. The company is operating very inefficient. -2
  • The TTM is -52,212.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-52,212.6%TTM-52,212.6%0.0%
TTM-52,212.6%YOY-2,761.6%-49,450.9%
TTM-52,212.6%5Y-12,152.6%-40,059.9%
5Y-12,152.6%10Y-6,316.2%-5,836.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-52,212.6%-221.8%-51,990.8%
TTM-52,212.6%-250.7%-51,961.9%
YOY-2,761.6%-208.5%-2,553.1%
3Y-19,274.2%-220.2%-19,054.0%
5Y-12,152.6%-342.4%-11,810.2%
10Y-6,316.2%-462.5%-5,853.7%
4.3.2.2. Operating Ratio

Measures how efficient Arovella is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 636.96 means that the operating costs are $636.96 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 636.957. The company is inefficient in keeping operating costs low. -1
  • The TTM is 636.957. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ636.957TTM636.9570.000
TTM636.957YOY24.850+612.106
TTM636.9575Y143.527+493.429
5Y143.52710Y74.037+69.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ636.9572.097+634.860
TTM636.9572.684+634.273
YOY24.8503.076+21.774
3Y229.4963.524+225.972
5Y143.5274.724+138.803
10Y74.0376.445+67.592
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arovella Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arovella is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 6.45Β means the company has $6.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 6.446. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.446. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.446TTM6.4460.000
TTM6.446YOY3.103+3.342
TTM6.4465Y3.851+2.595
5Y3.85110Y3.154+0.696
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4463.638+2.808
TTM6.4463.846+2.600
YOY3.1034.140-1.037
3Y4.6394.688-0.049
5Y3.8515.722-1.871
10Y3.1546.144-2.990
4.4.3.2. Quick Ratio

Measures if Arovella is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Arovella to theΒ Biotechnology industry mean.
  • A Quick Ratio of 6.23Β means the company can pay off $6.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 6.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.230TTM6.2300.000
TTM6.230YOY3.084+3.147
TTM6.2305Y3.646+2.584
5Y3.64610Y2.823+0.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2302.826+3.404
TTM6.2303.116+3.114
YOY3.0843.786-0.702
3Y4.4544.311+0.143
5Y3.6465.702-2.056
10Y2.8236.335-3.512
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arovella Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ArovellaΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Arovella to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15Β means that Arovella assets areΒ financed with 15.5% credit (debt) and the remaining percentage (100% - 15.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 0.155. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.155. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.155TTM0.1550.000
TTM0.155YOY0.309-0.154
TTM0.1555Y0.236-0.081
5Y0.23610Y0.209+0.027
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1550.327-0.172
TTM0.1550.349-0.194
YOY0.3090.332-0.023
3Y0.2120.340-0.128
5Y0.2360.346-0.110
10Y0.2090.378-0.169
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Arovella is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Arovella to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 18.3% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 0.183. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.183. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.183TTM0.1830.000
TTM0.183YOY0.447-0.264
TTM0.1835Y0.330-0.147
5Y0.33010Y0.283+0.047
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1830.383-0.200
TTM0.1830.438-0.255
YOY0.4470.414+0.033
3Y0.2800.450-0.170
5Y0.3300.457-0.127
10Y0.2830.512-0.229
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Arovella generates.

  • Above 15 is considered overpriced butΒ always compareΒ Arovella to theΒ Biotechnology industry mean.
  • A PE ratio of -18.97 means the investor is paying $-18.97Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is -11.927. Based on the earnings, the company is expensive. -2
  • The MRQ is -18.974. Based on the earnings, the company is expensive. -2
  • The TTM is -18.974. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.927MRQ-18.974+7.048
MRQ-18.974TTM-18.9740.000
TTM-18.974YOY-5.821-13.153
TTM-18.9745Y-9.152-9.823
5Y-9.15210Y-8.611-0.540
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.927-2.399-9.528
MRQ-18.974-2.092-16.882
TTM-18.974-2.625-16.349
YOY-5.821-3.784-2.037
3Y-9.319-3.762-5.557
5Y-9.152-6.363-2.789
10Y-8.611-7.055-1.556
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is -14.810. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -23.561. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -23.561. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.810MRQ-23.561+8.751
MRQ-23.561TTM-23.5610.000
TTM-23.561YOY-9.260-14.301
TTM-23.5615Y-13.372-10.190
5Y-13.37210Y-9.492-3.880
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.810-3.299-11.511
MRQ-23.561-2.742-20.819
TTM-23.561-3.801-19.760
YOY-9.260-4.402-4.858
3Y-12.270-5.140-7.130
5Y-13.372-8.483-4.889
10Y-9.492-9.296-0.196
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Arovella is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 14.78 means the investor is paying $14.78Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is 9.290. Based on the equity, the company is overpriced. -1
  • The MRQ is 14.780. Based on the equity, the company is expensive. -2
  • The TTM is 14.780. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD9.290MRQ14.780-5.490
MRQ14.780TTM14.7800.000
TTM14.780YOY15.679-0.899
TTM14.7805Y10.433+4.347
5Y10.43310Y5.751+4.682
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD9.2902.113+7.177
MRQ14.7801.856+12.924
TTM14.7802.125+12.655
YOY15.6792.454+13.225
3Y11.3462.492+8.854
5Y10.4333.668+6.765
10Y5.7514.364+1.387
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Total Other Income Expense Net -2,9321,637-1,295270-1,024-525-1,5493,6152,065



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets13,285
Total Liabilities2,057
Total Stockholder Equity11,228
 As reported
Total Liabilities 2,057
Total Stockholder Equity+ 11,228
Total Assets = 13,285

Assets

Total Assets13,285
Total Current Assets13,154
Long-term Assets131
Total Current Assets
Cash And Cash Equivalents 12,714
Other Current Assets 439
Total Current Assets  (as reported)13,154
Total Current Assets  (calculated)13,154
+/-0
Long-term Assets
Property Plant Equipment 131
Other Assets 0
Long-term Assets  (as reported)131
Long-term Assets  (calculated)131
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities2,041
Long-term Liabilities16
Total Stockholder Equity11,228
Total Current Liabilities
Short-term Debt 785
Accounts payable 984
Other Current Liabilities 1,057
Total Current Liabilities  (as reported)2,041
Total Current Liabilities  (calculated)2,825
+/- 785
Long-term Liabilities
Long-term Liabilities  (as reported)16
Long-term Liabilities  (calculated)0
+/- 16
Total Stockholder Equity
Common Stock104,296
Retained Earnings -95,506
Accumulated Other Comprehensive Income 2,438
Total Stockholder Equity (as reported)11,228
Total Stockholder Equity (calculated)11,228
+/-0
Other
Capital Stock104,296
Cash and Short Term Investments 12,714
Common Stock Shares Outstanding 941,423
Current Deferred Revenue136
Liabilities and Stockholders Equity 13,285
Net Debt -12,714
Net Invested Capital 11,228
Net Working Capital 11,113
Property Plant and Equipment Gross 338



6.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-30
> Total Assets 
6,117
3,144
4,653
16,096
14,951
16,629
20,998
16,064
16,611
11,902
13,526
9,755
10,729
20,347
22,821
19,515
20,016
16,642
16,253
6,707
10,687
9,212
5,471
13,285
13,2855,4719,21210,6876,70716,25316,64220,01619,51522,82120,34710,7299,75513,52611,90216,61116,06420,99816,62914,95116,0964,6533,1446,117
   > Total Current Assets 
4,342
1,152
1,220
7,357
5,556
6,212
7,869
6,234
8,009
2,793
5,779
3,054
2,432
7,485
9,344
5,293
4,610
1,071
5,595
2,035
7,343
6,588
5,219
13,154
13,1545,2196,5887,3432,0355,5951,0714,6105,2939,3447,4852,4323,0545,7792,7938,0096,2347,8696,2125,5567,3571,2201,1524,342
       Cash And Cash Equivalents 
4,326
643
726
3,767
1,827
975
835
489
2,899
834
3,561
1,590
753
3,990
6,252
2,449
1,770
98
4,314
977
6,717
6,071
5,175
12,714
12,7145,1756,0716,7179774,314981,7702,4496,2523,9907531,5903,5618342,8994898359751,8273,7677266434,326
       Short-term Investments 
0
0
0
0
0
1,220
1,885
117
119
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001191171,8851,22000000
       Net Receivables 
1
504
223
1,124
1,356
1,012
1,516
2,285
1,456
396
456
671
635
750
1,319
773
1,608
791
1,121
216
534
36
10
0
010365342161,1217911,6087731,3197506356714563961,4562,2851,5161,0121,3561,1242235041
       Other Current Assets 
15
4
5
88
188
307
48
412
3,291
1,538
1,121
77
241
957
233
939
122
84
115
819
617
480
33
439
4393348061781911584122939233957241771,1211,5383,29141248307188885415
   > Long-term Assets 
1,775
1,993
3,433
8,739
9,395
10,417
13,130
9,830
8,602
9,110
7,747
6,700
8,297
12,862
13,476
14,222
15,405
15,571
10,658
4,673
3,344
2,625
252
131
1312522,6253,3444,67310,65815,57115,40514,22213,47612,8628,2976,7007,7479,1108,6029,83013,13010,4179,3958,7393,4331,9931,775
       Property Plant Equipment 
10
77
1,083
1,816
1,904
2,266
2,441
4,919
4,568
105
100
60
117
312
389
272
232
173
367
422
433
371
50
131
13150371433422367173232272389312117601001054,5684,9192,4412,2661,9041,8161,0837710
       Goodwill 
0
0
0
4,085
4,177
4,635
6,048
2,355
959
966
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000009669592,3556,0484,6354,1774,085000
       Intangible Assets 
1,765
1,765
2,066
2,476
2,503
2,503
2,493
2,493
2,193
8,988
7,646
6,640
8,180
12,549
13,088
13,951
15,173
15,399
10,291
4,251
2,911
2,253
0
0
002,2532,9114,25110,29115,39915,17313,95113,08812,5498,1806,6407,6468,9882,1932,4932,4932,5032,5032,4762,0661,7651,765
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,119
2,779
2,121
0
0
002,1212,7794,1190000000000000000000
> Total Liabilities 
4
146
885
2,821
3,227
3,278
6,671
5,554
7,769
3,557
2,494
2,743
4,039
4,355
3,520
2,909
3,163
5,178
2,276
2,572
1,706
1,595
1,691
2,057
2,0571,6911,5951,7062,5722,2765,1783,1632,9093,5204,3554,0392,7432,4943,5577,7695,5546,6713,2783,2272,8218851464
   > Total Current Liabilities 
4
101
617
2,287
2,763
1,804
5,103
5,334
5,933
2,283
2,494
2,743
3,439
2,480
3,520
2,909
1,361
3,835
1,349
2,022
1,695
1,509
1,682
2,041
2,0411,6821,5091,6952,0221,3493,8351,3612,9093,5202,4803,4392,7432,4942,2835,9335,3345,1031,8042,7632,2876171014
       Short-term Debt 
3
21
229
1,538
2,013
1,124
2,549
3,233
2,468
719
1,194
701
562
0
1,725
1,730
0
2,023
36
-93
-124
-274
0
785
7850-274-124-93362,02301,7301,72505627011,1947192,4683,2332,5491,1242,0131,538229213
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36
12
6
1
0
0
00161236000000000000000000
       Accounts payable 
0
80
150
620
517
291
2,318
1,314
1,737
1,336
947
979
968
1,681
1,578
994
1,361
353
512
732
227
752
773
984
9847737522277325123531,3619941,5781,6819689799471,3361,7371,3142,318291517620150800
       Other Current Liabilities 
1
81
238
128
233
389
236
787
1,728
228
353
1,062
1,909
799
217
186
0
1,459
801
333
1,197
349
756
1,057
1,0577563491,1973338011,45901862177991,9091,0623532281,728787236389233128238811
   > Long-term Liabilities 
0
45
268
534
463
1,474
1,568
220
1,835
1,274
61
0
600
1,875
0
0
1,803
1,342
927
550
11
87
9
16
16987115509271,3421,803001,8756000611,2741,8352201,5681,474463534268450
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,803
26
17
4
3
77
0
0
00773417261,8030000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
545
8
9
9
0
09985450000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,119
2,779
2,121
0
0
002,1212,7794,1190000000000000000000
> Total Stockholder Equity
6,113
2,998
3,767
13,275
11,725
13,351
14,327
10,264
8,842
8,346
11,032
7,012
6,690
13,949
17,269
16,606
16,852
11,465
13,977
4,135
8,982
7,617
3,780
11,228
11,2283,7807,6178,9824,13513,97711,46516,85216,60617,26913,9496,6907,01211,0328,3468,84210,26414,32713,35111,72513,2753,7672,9986,113
   Common Stock
6,565
4,070
5,905
16,380
16,759
17,704
20,818
26,377
29,192
31,740
38,621
38,858
40,129
48,945
55,574
55,717
57,139
57,205
67,386
67,386
77,003
83,536
88,872
104,296
104,29688,87283,53677,00367,38667,38657,20557,13955,71755,57448,94540,12938,85838,62131,74029,19226,37720,81817,70416,75916,3805,9054,0706,565
   Retained Earnings -95,506-87,055-77,025-68,472-64,889-55,712-47,917-42,458-41,163-38,932-35,565-33,513-33,268-28,758-24,249-19,228-15,791-6,416-4,876-5,034-3,105-2,138-1,072-451
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
-1
0
0
0
0
-176
-434
-1,399
0
86
158
0
0
0
-56
0
0
0
1,630
451
1,105
1,964
0
01,9641,1054511,630000-56000158860-1,399-434-1760000-10



6.4. Balance Sheets

Currency in AUD. All numbers in thousands.




6.5. Cash Flows

Currency in AUD. All numbers in thousands.




6.6. Income Statements

Currency in AUD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue17
Cost of Revenue-43
Gross Profit17-26
 
Operating Income (+$)
Gross Profit17
Operating Expense-10,785
Operating Income-10,811-10,768
 
Operating Expense (+$)
Research Development6,735
Selling General Administrative2,771
Selling And Marketing Expenses1,279
Operating Expense10,78510,785
 
Net Interest Income (+$)
Interest Income139
Interest Expense-9
Other Finance Cost-0
Net Interest Income130
 
Pretax Income (+$)
Operating Income-10,811
Net Interest Income130
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-8,746-12,876
EBIT - interestExpense = -8,885
-10,681
-8,737
Interest Expense9
Earnings Before Interest and Taxes (EBIT)-8,876-8,737
Earnings Before Interest and Taxes (EBITDA)-8,833
 
After tax Income (+$)
Income Before Tax-8,746
Tax Provision-0
Net Income From Continuing Ops-8,746-8,746
Net Income-8,746
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses10,828
Total Other Income/Expenses Net2,065-130
 

Technical Analysis of Arovella
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arovella. The general trend of Arovella is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arovella's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Arovella Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arovella Therapeutics Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.11 < 0.12 < 0.12.

The bearish price targets are: 0.088 > 0.083 > 0.072.

Know someone who trades $ALA? Share this with them.πŸ‘‡

Arovella Therapeutics Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arovella Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arovella Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arovella Therapeutics Ltd. The current macd is 0.00146515.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Arovella price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Arovella. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Arovella price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Arovella Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartArovella Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arovella Therapeutics Ltd. The current adx is 19.74.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arovella shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Arovella Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arovella Therapeutics Ltd. The current sar is 0.11609971.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Arovella Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arovella Therapeutics Ltd. The current rsi is 47.75. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Arovella Therapeutics Ltd Daily Relative Strength Index (RSI) ChartArovella Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arovella Therapeutics Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arovella price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Arovella Therapeutics Ltd Daily Stochastic Oscillator ChartArovella Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arovella Therapeutics Ltd. The current cci is -61.54502774.

Arovella Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartArovella Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arovella Therapeutics Ltd. The current cmo is -11.32286921.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Arovella Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartArovella Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arovella Therapeutics Ltd. The current willr is -91.42857143.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Arovella Therapeutics Ltd Daily Williams %R ChartArovella Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Arovella Therapeutics Ltd.

Arovella Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arovella Therapeutics Ltd. The current atr is 0.00704796.

Arovella Therapeutics Ltd Daily Average True Range (ATR) ChartArovella Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arovella Therapeutics Ltd. The current obv is 62,102,093.

Arovella Therapeutics Ltd Daily On-Balance Volume (OBV) ChartArovella Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arovella Therapeutics Ltd. The current mfi is 40.03.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Arovella Therapeutics Ltd Daily Money Flow Index (MFI) ChartArovella Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arovella Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-11STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Arovella Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arovella Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.752
Ma 20Greater thanMa 500.094
Ma 50Greater thanMa 1000.085
Ma 100Greater thanMa 2000.095
OpenGreater thanClose0.088
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Arovella with someone you think should read this too:
  • Are you bullish or bearish on Arovella? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arovella? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arovella Therapeutics Ltd

I send you an email if I find something interesting about Arovella Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Arovella Therapeutics Ltd.

Receive notifications about Arovella Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.